Jeremy P. M. Flanagan

Jeremy P. M. Flanagan

Auto-generated profile, based on publicly available information

Jeremy P. M. Flanagan

Department of Ophthalmology The Royal Victorian Eye and Ear Hospital East Melbourne Victoria Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2022 in Clinical and Experimental Optometry
Verified
Journal Article
Closed access
JFJeremy Pm Flanagan
Jeremy Pm Flanagan
RORoderick O'Day
Roderick O'Day
KRKelsey A Roelofs
Kelsey A Roelofs
MMMyra McGuinness
Myra McGuinness
PWPeter van Wijngaarden
Peter van Wijngaarden
BDBertil E Damato
Bertil E Damato
Although melanocytic choroidal tumours of the choroid are a common eye pathology, no standardised protocol exists for their management in the community.Choroidal naevi are found in approximately 6%...

10 October 2022 in Anaesthesia and Intensive Care
Verified
Journal Article
Closed access
RCRahul Costa-pinto
Rahul Costa-pinto
FYFumitaka Yanase
Fumitaka Yanase
LKLucy M Kennedy
Lucy M Kennedy
LTLachie J Talbot
Lachie J Talbot
JFJeremy Pm Flanagan
Jeremy Pm Flanagan
DJDaryl A Jones
Daryl A Jones
Postoperative ‘enhanced care’ models that sit between critical care and ward-based care may allow for more cost-effective and efficient utilisation of resources for high-risk surgical patients. In this retrospective observational study, we describe an overnight intensive recovery model in a tertiary hospital, termed ‘recovery high dependency unit’, and the characteristics, treatment, disposition at discharge and in-hospital outcomes of patients admitted to this unit. We included all adult patients (≥18 years) admitted to the recovery high dependency unit for at least one hour between July 2017 and June 2020. Over this three-year period, 1257 patients were included in the study. The median length of stay in the recovery high dependency unit was 12.6 (interquartile range 9.1–15.9) hours and the median length of hospital stay was 8.3 (interquartile range 5.0–17.3) days. Hospital discharge data showed that 1027 (81.7%) patients were discharged home and that 37 (2.9%) patients died. Non-invasive ventilation was delivered to 59 (4.7%) patients and 290 (23.1%) required vasopressor support. A total of 164 patients (13.0%) were admitted to the intensive care unit following their recovery high dependency unit admission. Of the 1093 patients who were discharged to the ward, 70 patients (6.4%) had a medical emergency team call within 24 hours of discharge from the recovery high dependency unit. In this study of a recovery high dependency unit patient cohort, there was a relatively low need for intensive care unit admission postoperatively and a very low incidence of medical emergency team calls post-discharge to the ward. Other institutions may consider the introduction and evaluation of this model in the care of their higher risk surgical patients.

25 January 2023 in Journal of Orthopaedic Reports
Verified
Journal Article
Open access
JFJeremy P.M. Flanagan
Jeremy P.M. Flanagan
KYKen Ye
Ken Ye
JSJarrad M. Stevens
Jarrad M. Stevens
CBClaudia Di Bella
Claudia Di Bella

9 July 2024 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Closed access
JFJeremy P. M. Flanagan
Jeremy P. M. Flanagan
MMMelissa Moyes
Melissa Moyes
TGTodd Goodwin
Todd Goodwin
CCCarmel Crock
Carmel Crock
TCThomas G. Campbell
Thomas G. Campbell

4 April 2024 in Canadian Journal of Ophthalmology
Verified
Journal Article
Open access
JFJeremy P.M. Flanagan
Jeremy P.M. Flanagan
LFLotte S. Fog
Lotte S. Fog
MAMelvin A. Astrahan
Melvin A. Astrahan
LTLachie J. Talbot
Lachie J. Talbot
DMDaniel McKay
Daniel McKay
RORoderick O'Day
Roderick O'Day
Ruthenium-106 brachytherapy is commonly used to treat uveal melanomas. Most centres prescribe a radiation dose to the tumour apex that is calculated with the tumour located in the centre of the plaque. Recent work suggests that D99%-the minimum radiation dose delivered to 99% of tumour volume-may be a better predictor of tumour control than apex dose. Both dosing regimens may be affected by tumour and treatment variables differently. We explored the effect of differences in these variables on volume and apex dose using a 3-dimensional planning model. The time required to deliver 100 Gy to the tumour apices of representative tumours ranging from 2- to 6-mm thickness with central plaque positioning was calculated in Plaque Simulator™. This treatment time was used for further calculations, including D99% with central plaque placement, and apical and tumour volume doses when tumour and plaque characteristics were altered, including eccentric plaque placement, either away from (tilt) or along (offset) scleral surface, tumour shape, and plaque type. D99% was always greater than the apex dose when plaques were placed centrally, and the difference increased with tumour thickness. Increasing degrees of tumour offset reduced apical dose and D99%, with a greater effect on apical dose for thicker and D99% for thinner tumours, respectively. Differences in tumour shape and plaque type had idiosyncratic effects on apical and volume dosing. D99% and apex dose are affected by tumour and treatment characteristics in different ways, highlighting the complexity of radiation delivery to uveal tumours.